GlobeNewswireNOV 144 min read$GALT

Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update

NORCROSS, Ga., Nov. 14, 2025 ( GLOBE NEWSWIRE ) -- Galectin Therapeutics, Inc. ( NASDAQ: GALT ) , the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three and nine months ended September 30, 2025.

Original reporting

GlobeNewswire · Galectin Therapeutics Inc.

Published Nov 14, 2025, 1:00 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Nov 15, 2025, 12:32 AM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update — source image — Source · www.globenewswire.com

Decision brief

The 30-second read

$GALTNeutralLow

Why it matters

The news suggests steady progress but lacks major catalysts; traders should monitor upcoming clinical data or regulatory updates.

Market read

The company's developments are relevant within biotech and life sciences sectors, with potential sector-wide implications.

What to watch

Potential upcoming clinical trial results or regulatory decisions could significantly influence stock price.

Timing: short-term

Background

Galectin Therapeutics is advancing therapeutics targeting galectin proteins, with recent financial results indicating ongoing development and stability.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$GALTNeutralMedium confidence

Context

Primary focus due to recent financial results and business update.

Expected impact

Limited immediate impact; potential for moderate positive movement if results meet expectations.

Evidence & confidence

Financial reports and business updates typically cause short-term price movements; however, without significant surprises, the impact remains moderate.

Market effects

Sector

Potential positive sentiment in biotech and life sciences sectors due to ongoing development efforts.

Regional

Limited regional impact; company primarily influences local biotech markets.

Global

Moderate; biotech sector's global relevance may influence related indices.

Counterpoint

What could challenge this read

The financial results may be below market expectations, leading to a short-term decline.

Key entities

Company
Galectin Therapeutics Inc.
Developer of therapeutics targeting galectin proteins.

Read at source ← All news

AUG 14

$GALTMedAI 8/10

Galectin Therapeutics Inc.: Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update

Galectin Therapeutics (NASDAQ:GALT) reported Q2 2026 results for the three months ended June 30, 2026 and said it reached agreement with the FDA on Phase 3 belapectin trial elements for MASH cirrhosis and portal hypertension, targeting protocol submission in 3Q 2026. Cash was $13.2M; net loss was $9.2M ($0.14/share). Chairman Uihlein converted about $105.8M debt into 34.4M shares.

finanznachrichten.de4 min

AUG 14

$GALTMed

GALECTIN THERAPEUTICS INC (GALT): Results of Operations and Financial Condition

GALECTIN THERAPEUTICS INC (GALT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update NORCROSS, Ga., August 14, 2026 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reporte

SEC EDGAR 8-K6 min

AUG 4

$GALTMedAI 8/10

Galectin Therapeutics Inc.: Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet

Galectin Therapeutics (NASDAQ: GALT) said Chairman Richard E. Uihlein converted all outstanding principal and accrued interest under five line-of-credit facilities into common stock effective July 31, 2026. The deal eliminated about $105.8 million of debt (about $91.0 million principal, $14.8 million interest) and issued 34,376,167 shares at a blended $3.07 conversion price. A sixth $10 million facility remains undrawn.

finanznachrichten.de4 min

JUL 14

$QTTBMedAI 8/10

Top Biotech Gainers: QTTB Sends Strong SIGNAL; AMWL And SI In Focus

Biotech gainers highlighted Q32 Bio (QTTB), up 90.7% to $21.38 after positive Phase 2 SIGNAL-AA results for bempikibart in alopecia areata, and it launched a $200M underwritten stock offering. Agenus (AGEN) rose 82.7% to $6.12 on a planned ~$85M private placement for BOT+BAL Phase 3 ROBBIN1. Other movers: ACTU, GALT, AMWL, SI.

rttnews.com7 min

AUG 28

$MAIRMedAI 8/10

Billionaire Tycoon Ernesto Bertarelli Buys $219 Million in Madison Air Solutions Shares. What Does This Mean for Investors?

Billionaire Ernesto Bertarelli indirectly purchased 8.8 million shares of Madison Air Solutions (MAIR) at $24.97 per share, totaling $219 million. The acquisition was made through K.C. Armada, LP, bringing his indirect ownership to 11% of the company. MAIR's stock closed at $28.51, a 14% premium over the purchase price. The company has a market cap of $14.3 billion and expects 18% revenue growth this fiscal year.

fool.com2 min